

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



李 氏 大 藥 廠

## **Lee's Pharmaceutical Holdings Limited**

**李 氏 大 藥 廠 控 股 有 限 公 司 \***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 950)**

### **RESIGNATION AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The Board announces that:

- (a) Dr. Marco Maria Brughera has resigned as a non-executive director of the Company with effect from 29 December 2017; and
- (b) Mr. Simon Miles Ball has been appointed as a non-executive director of the Company with effect from 29 December 2017.

#### **RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Dr. Marco Maria Brughera (“**Dr. Brughera**”) has tendered his resignation as a non-executive director of the Company (the “**Director**”) with effect from 29 December 2017 as he would like to devote more time to the development of his personal business and interests. Upon the resignation of Dr. Brughera taking effect, he will no longer hold any position in the Group.

Dr. Brughera has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

#### **APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The Board also announces that Mr. Simon Miles Ball (“**Mr. Ball**”) has been appointed as a non-executive Director with effect from 29 December 2017.

\* *For identification purpose only*

Mr. Ball, aged 39, has more than 17 years of business and management experience within the pharmaceutical industry. He is currently the Global Head of Business Development of the Leadiant Biosciences Group (formerly Sigma Tau Group), a position he has held since May 2014. He also serves as Country General Manager in United Kingdom, Ireland and Nordics in Leadiant Biosciences Ltd. and he is a member of the board of directors of Leadiant Biosciences Ltd. in United Kingdom and Exelead Inc. in the United States of America (formerly known as PharmaSource Inc., the manufacturing company within the Leadiant Biosciences Group). Mr. Ball is also a consultant of Qualister SA, which is a substantial shareholder of the Company.

Between October 2011 and April 2014, Mr. Ball held a number of senior positions within GlaxoSmithKline, initially as Head of Business Development Australia and later as the Head of Business Development for Asia Pacific, North Asia and other developing markets. After collaborating with SR One (GlaxoSmithKline's corporate venture capital company) whilst serving GlaxoSmithKline, Mr. Ball subsequently spent time providing consulting services to SR One whilst leading a strategic business unit divestment.

Between July 2004 and October 2011, Mr. Ball held several senior positions in the areas of Business Development, Corporate Development and Emerging Markets with Cephalon Inc. (formerly known as Zeneus Pharma Ltd), EUSA Pharma Ltd. and Takeda Pharmaceutical Company Limited.

Mr. Ball obtained his degree in physiology from the University of Leeds.

Mr. Ball was selected to serve as a member of the Board because of his experience in the areas of drug discovery and development and his experience as an executive officer and a director in the pharmaceutical industry.

On 29 December 2017, the Company has entered into a letter of appointment with Mr. Ball, pursuant to which Mr. Ball has been appointed as a non-executive Director for a term of 3 years commencing from 29 December 2017, which may be terminated by either party by two months' notice in writing. Mr. Ball is subject to retirement by rotation and re-election at the next annual general meeting of the Company in accordance with the articles of association of the Company. Mr. Ball will receive a director's fee of HK\$144,000 per annum, which is determined by the remuneration committee of the Company and the Board with reference to his duties and responsibilities within the Company. Mr. Ball is also entitled to participate in the share option scheme of the Company.

Save as disclosed above, Mr. Ball (a) did not hold any other directorships in the last three years in public companies the securities of which are listed on any securities market in Hong Kong or overseas; (b) does not have any other major appointments and professional qualifications; (c) does not hold any position in the Company or any subsidiaries of the Company; (d) does not have any relationship with any directors, senior management or substantial or controlling shareholder of the Company; and (e) does not have any interests in the shares of the Company as at the date of this announcement within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Board is not aware of any other matters in relation to Mr. Ball that needs to be brought to the attention of the shareholders of the Company nor is there any information to be disclosed by the Company pursuant to any of the requirements under rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange.

The Board would like to express its sincere gratitude to Dr. Brughera for his valuable contributions to the Company during his tenure of office and wish to extend its warmest welcome to Mr. Ball for joining the Board.

By order of the Board  
**Lee's Pharmaceutical Holdings Limited**  
**Lee Siu Fong**  
*Chairman*

Hong Kong, 29 December 2017

*As at the date thereof, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive Directors; Mr. Simon Miles Ball is a non-executive Director; Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.*